JAMA Internal Medicine published the study.
Here are five points:
1. The study found industry payments to Massachusetts physicians correlated with higher brand-name drug prescriptions for high cholesterol.
2. A physician’s brand-name statin prescribing rate increased 0.1 percent for every $1,000 in industry payment.
3. Brand-name statins exceed generics cost by two to four times.
4. The researchers clarified many factors impact the brand-name prescribing rates, and they are not suggesting a causal relationship.
5. The study authors hope the results will push for reduced industry influence.
More articles on practice management:
How many PAs, NPs do medical practices typically employ? 5 statistics
Is a little patient mistrust always a bad thing? 4 thoughts
FDA panel supports mandatory opioid training for physicians — 5 findings from the FDA’s ER/LA REMS assessments
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
